Founded by Bernie Schaeffer, we provide stock news, options insights, and premium trading services to options traders

 

BACKED BY 170+ YEARS OF MARKET EXPERTISE

Get Schaeffer’s market outlook every Monday, straight to your inbox.

 

 
 
 
 
 
 
 
 
X
Investor pointing to price action chart
Quantum computing stocks soared on Friday as traders targeted tech stocks amid the broader market rebound. Nvidia's (NVDA) semi-annual GTC conference -- hailed as a top artificial intelligence (AI) ev ... Quantum computing stocks soared on Friday as traders targeted tech stocks amid the broader market rebound. Nvidia's (NVDA) semi-annual GTC conference -- hailed as a top artificial intelligence (AI) event -- is putting the sector back in the spotlight as well. Per the company, CEO Jensen Huang plans ... Keep Reading
Schaeffer’s Midday Market Check Daily Newsletter
The Dow Jones Industrial Average (DJI) is boasting a 247-point midday lead while the S&P 500 Index (SPX) is trading near breakeven, as Wall Street attempts to bounce back from its worst week in t ... The Dow Jones Industrial Average (DJI) is boasting a 247-point midday lead while the S&P 500 Index (SPX) is trading near breakeven, as Wall Street attempts to bounce back from its worst week in two years. Retail sales data is boosting sentiment despite missing estimates, not quite touching the ... Keep Reading
Analyst upgrade, Stock upgrade, Stock rating, Analyst news, Buy rating
Shares of Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) were last seen up 2.3% at $19.62 today, after an upgrade from J.P. Morgan Securities to "overweight" from "neutral." The firm cited a favorable ... Shares of Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) were last seen up 2.3% at $19.62 today, after an upgrade from J.P. Morgan Securities to "overweight" from "neutral." The firm cited a favorable risk-reward setup, leaving its price target at $30. Today's bull note comes after Zacks Research l ... Keep Reading
Pharmacy stocks, Pharmaceutical stocks, Vaccine stocks
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective f ... Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants. Shares are on pace for their fourth loss over the last five sessions, as we ... Keep Reading